AU2018319637B2 - Expression control using a regulatable intron - Google Patents

Expression control using a regulatable intron Download PDF

Info

Publication number
AU2018319637B2
AU2018319637B2 AU2018319637A AU2018319637A AU2018319637B2 AU 2018319637 B2 AU2018319637 B2 AU 2018319637B2 AU 2018319637 A AU2018319637 A AU 2018319637A AU 2018319637 A AU2018319637 A AU 2018319637A AU 2018319637 B2 AU2018319637 B2 AU 2018319637B2
Authority
AU
Australia
Prior art keywords
leu
gly
sequence
ala
intron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018319637A
Other languages
English (en)
Other versions
AU2018319637A1 (en
Inventor
Graham WHYTESIDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AskBio UK Ltd
Original Assignee
AskBio UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AskBio UK Ltd filed Critical AskBio UK Ltd
Publication of AU2018319637A1 publication Critical patent/AU2018319637A1/en
Assigned to ASKBIO UK LTD reassignment ASKBIO UK LTD Amend patent request/document other than specification (104) Assignors: SYNPROMICS LIMITED
Application granted granted Critical
Publication of AU2018319637B2 publication Critical patent/AU2018319637B2/en
Priority to AU2025205352A priority Critical patent/AU2025205352A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018319637A 2017-08-23 2018-08-22 Expression control using a regulatable intron Active AU2018319637B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205352A AU2025205352A1 (en) 2017-08-23 2025-07-10 Expression control using a regulatable intron

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1713545.0 2017-08-23
GBGB1713545.0A GB201713545D0 (en) 2017-08-23 2017-08-23 Expression control using a regulatable intron
PCT/GB2018/052387 WO2019038544A1 (en) 2017-08-23 2018-08-22 EXPRESSION CONTROL USING AN ADJUSTABLE INTRON

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205352A Division AU2025205352A1 (en) 2017-08-23 2025-07-10 Expression control using a regulatable intron

Publications (2)

Publication Number Publication Date
AU2018319637A1 AU2018319637A1 (en) 2020-03-12
AU2018319637B2 true AU2018319637B2 (en) 2025-04-10

Family

ID=59996625

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018319637A Active AU2018319637B2 (en) 2017-08-23 2018-08-22 Expression control using a regulatable intron
AU2025205352A Pending AU2025205352A1 (en) 2017-08-23 2025-07-10 Expression control using a regulatable intron

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205352A Pending AU2025205352A1 (en) 2017-08-23 2025-07-10 Expression control using a regulatable intron

Country Status (8)

Country Link
US (2) US11492618B2 (enExample)
EP (1) EP3673068A1 (enExample)
JP (2) JP7830029B2 (enExample)
CN (2) CN111566216B (enExample)
AU (2) AU2018319637B2 (enExample)
GB (1) GB201713545D0 (enExample)
IL (2) IL314845A (enExample)
WO (1) WO2019038544A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3171636A1 (en) * 2020-03-26 2021-09-30 Graham WHYTESIDE Forskolin-inducible promoters and hypoxia-inducible promoters
US20230407327A1 (en) * 2020-03-26 2023-12-21 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production
WO2021209743A1 (en) * 2020-04-15 2021-10-21 Synpromics Limited Forskolin-inducible promoters and hypoxia-inducible promoters
JP7898267B2 (ja) * 2021-10-20 2026-07-31 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
WO2025024776A2 (en) * 2023-07-27 2025-01-30 Duke University Compositions comprising xbp1 fragments and methods of use in gene therapy
WO2026015884A1 (en) * 2024-07-11 2026-01-15 Helix Nanotechnologies Inc Compositions comprising ire-1 binding sequences and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151827A1 (en) * 2009-06-25 2010-12-29 Bayer Healthcare Llc X-box binding proteins (xbp-1) variants and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP4446057B2 (ja) * 2002-08-28 2010-04-07 独立行政法人理化学研究所 生体刺激存在下でのｍＲＮＡのフレームシフトを利用した蛋白質の発現方法
AU2003268356A1 (en) * 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
US20070111258A1 (en) * 2005-06-22 2007-05-17 Kaufman Randal J Compositions and methods for modulating the acute phase response
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
US20200393447A1 (en) * 2017-07-09 2020-12-17 Thomas Hughes Biosensors for measuring cell signaling in stressed and healthy cells
WO2021195491A2 (en) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151827A1 (en) * 2009-06-25 2010-12-29 Bayer Healthcare Llc X-box binding proteins (xbp-1) variants and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shamu (Current Biology, 8, 4, R121 -R123, 1998). *

Also Published As

Publication number Publication date
EP3673068A1 (en) 2020-07-01
JP2023118937A (ja) 2023-08-25
US11492618B2 (en) 2022-11-08
AU2018319637A1 (en) 2020-03-12
JP2020533019A (ja) 2020-11-19
US20200199593A1 (en) 2020-06-25
JP7830029B2 (ja) 2026-03-16
IL314845A (en) 2024-10-01
CA3073366A1 (en) 2019-02-28
IL272800B1 (en) 2024-09-01
NZ761945A (en) 2024-09-27
GB201713545D0 (en) 2017-10-04
CN111566216B (zh) 2024-07-02
IL272800B2 (en) 2025-01-01
WO2019038544A1 (en) 2019-02-28
AU2025205352A1 (en) 2025-07-31
IL272800A (en) 2020-04-30
US12600969B2 (en) 2026-04-14
CN118562839A (zh) 2024-08-30
CN111566216A (zh) 2020-08-21
US20230304003A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
AU2009212833B2 (en) Sirna-mediated gene silencing with viral vectors
US12600969B2 (en) Expression control using a regulatable intron
US20040023390A1 (en) SiRNA-mediated gene silencing with viral vectors
EP2982758A1 (en) Genome editing for the treatment of huntington's disease
CN1938428A (zh) 多基因表达的质粒系统
CN101213203A (zh) 在转录后水平调节核酸表达的方法和组合物
CN113166779A (zh) 调控的基因编辑系统
JP2003534775A (ja) タンパク質を不安定化する方法とその使用
EP1499735B1 (en) Optimization of transgene expression in mammalian cells
KR20230056630A (ko) 신규의 omni-59, 61, 67, 76, 79, 80, 81 및 82 crispr 뉴클레아제
US12472269B2 (en) Liver-specific inducible promoters and methods of use thereof
JP2026509506A (ja) リボザイム媒介ｒｎａアセンブリおよび発現
CA3073366C (en) Expression control using a regulatable intron
HK40054920A (en) Regulated gene editing system
HK40114268A (en) Expression control using a regulatable intron
HK40056629B (en) Liver-specific inducible promoters and methods of use thereof
HK40056629A (en) Liver-specific inducible promoters and methods of use thereof
HK40092447A (en) Novel omni-59, 61, 67, 76, 79, 80, 81, and 82 crispr nucleases
CA2558640A1 (en) Spliceosome mediated rna trans-splicing
AU2004237883A1 (en) Spliceosome mediated RNA trans-splicing
AU2005200828A1 (en) siRNA-mediated gene silencing with viral vectors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ASKBIO UK LTD

Free format text: FORMER NAME(S): SYNPROMICS LIMITED

FGA Letters patent sealed or granted (standard patent)